Streetbeat News

Regulatory

USPH

US Physical Therapy Inc has filed for a mixed shelf offering with the SEC, but the size of the offering has not been disclosed.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:30 pm

SPY

The Biden administration has requested a U.S. court to dismiss a case challenging the federal mask mandate for airplanes, as the Covid health emergency has expired. This could potentially impact airline stocks.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:28 pm

IYH

SPY

The CMS announced a new HHS proposal aimed at increasing transparency on prescription drug costs and saving money for states and the federal government in Medicaid. The proposal includes steps to further drive down drug costs in the program.

Portfolio Pulse from Bill Haddad

May 23, 2023 | 8:24 pm

HYZN

Hyzon Motors (NASDAQ:HYZN) received a Second Additional Staff Determination from Nasdaq due to not filing its Q1 2023 Form 10-Q, resulting in non-compliance with Nasdaq's Listing Rules. Hyzon has until May 24, 2023, to present its views on the deficiency, and the Nasdaq Hearings Panel granted an extension to file the Q1 2023 Form 10-Q by June 7, 2023.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:23 pm

IYH

SPY

The Biden-Harris administration has announced a proposal to advance prescription drug transparency in Medicaid, aiming to lower drug costs and increase access to medications for beneficiaries.

Portfolio Pulse from Bill Haddad

May 23, 2023 | 8:21 pm

INO

INOVIO has secured Orphan Drug Designation for INO-3107 from the European Commission for the treatment of Recurrent Respiratory Papillomatosis.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:15 pm

UTRS

Minerva Surgical has been granted U.S. Patent #11653972 for its medical systems and methods for resecting and extracting tissue. This patent could potentially strengthen Minerva's position in the medical device market.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:15 pm

WLDS

Wearable Devices Ltd. (NASDAQ: WLDS) has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price rule. The company now has until November 20, 2023, to meet the $1.00 per share requirement.

Portfolio Pulse from Happy Mohamed

May 23, 2023 | 8:07 pm

GLPG

Galapagos has announced the start of a Phase 2 study with its selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis. This marks a significant step in the development of the drug.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:04 pm

PHAT

Phathom Pharmaceuticals has resubmitted its New Drug Application (NDA) for vonoprazan, a treatment for Erosive GERD, to the FDA. If approved, a combined U.S. commercial launch for Erosive GERD and H. pylori indications is planned for Q4 2023.

Portfolio Pulse from Benzinga Newsdesk

May 23, 2023 | 8:02 pm